Cytek Biosciences (CTKB) vs Nautilus Biotechnology (NAUT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nautilus Biotechnology (NAUT) has outperformed Cytek Biosciences (CTKB) over the past year, gaining 101.8% versus a gain of 37.4%. Over five years, NAUT leads with a -68.1% price change compared with -77.7% for CTKB. Cytek Biosciences is the larger company by market cap ($696.7 million vs $231.6 million), about 3.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTKB | NAUT |
|---|---|---|
| Share price | $5.36 | $1.82 |
| Market cap | $696.71M | $231.60M |
| 1-day change | +0.37% | -7.14% |
| YTD return | +6.14% | -6.67% |
| 1-year return | +37.44% | +101.77% |
| 5-year return | -77.73% | -68.13% |
| Forward P/E | 76.57 | — |
| EPS (TTM) | $-0.62 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.21 | $4.31 |
| 52-week low | $3.31 | $0.82 |
| Distance from 52-week high | -13.69% | -57.77% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +3.73% | +110.44% |
| Average volume | 1.05M | 2.66M |
| Shares outstanding | 129.98M | 127.26M |
| Employees | 682 | 127 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Cytek Biosciences is about 3.0 times larger than Nautilus Biotechnology by market value ($696.71M vs $231.60M).
- NAUT has outperformed CTKB by 64.3 percentage points over the past year.
About Cytek Biosciences
CTKB stock →Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems.
Industrials · Biotechnology: Laboratory Analytical Instruments · 682 employees
About Nautilus Biotechnology
NAUT stock →Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.
Industrials · Biotechnology: Laboratory Analytical Instruments · 127 employees
CTKB vs NAUT FAQ
Which is bigger, Cytek Biosciences or Nautilus Biotechnology?
Cytek Biosciences (CTKB) is larger, with a market capitalization of $696.71M compared with $231.60M for Nautilus Biotechnology (NAUT).
Which stock has performed better over the past year, CTKB or NAUT?
NAUT returned +101.77% over the past 12 months, compared with +37.44% for CTKB (price return, excluding dividends). Past performance does not predict future results.
Are Cytek Biosciences and Nautilus Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.